Year : 2018 | Volume
: 4 | Issue : 3 | Page : 82--89
Sclerostin level in rheumatoid arthritis patients and its relationship to disease severity and bone mineral density
Abdel Megid Mona1, Barakat Barakat2, Ayad Mona3, Abdel Ghani Eman1, Bakri Heba1
1 Department of Internal Medicine, Rheumatology, and Clinical Immunology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
2 Department of Radiodiagnosis, Faculty of Medicine, Alexandria University, Alexandria, Egypt
3 Department of Clinical and Chemical Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
Background Bone loss in rheumatoid arthritis is caused by increased bone resorption without increasing bone formation. The Wnt pathway is important in the control of bone formation through the regulation of osteoblast activity. Sclerostin is an important regulator of the Wnt pathway by blocking Wnt binding to its receptor and thereby , inhibiting bone formation.
Aim Of The Work was to correlate the relation between level of serum sclerostin and bone mineral density with disease severity in rheumatoid arthritis patients.
Subjects The study was conducted on 50 subjects divided into two groups: Group I : Thirty patients of rheumatoid arthritis subjects diagnosed according to 2010 ACR / EULAR diagnostic criteria. Group II : Twenty persons as a control group.
Methods All patients were subjected to ; thorough medical history taking, DAS -28, disability Index, complete blood count (CBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), RF, antinuclear antibody (ANA), Anti-CCP Antibodies, Human Sclerostin levels using ELISA technique, Plain X- ray on both hands and feets, U/S on both hands, and (DEXA) scan.
Results There was a statistical significant difference between the two studied groups regarding the age, gender, sclerostin level, and DAS-28 (P>0.05).
Conclusion Most of patients were under treatment with disease modifying anti-rheumatic drugs (DMARDs) as methotrexate, fracture risk was not assessed, and measurements for renal function were not measured. However, it is possible that circulating sclerostin levels may not reflect changes of sclerostin at a local level. Despite the many questions that remain, pre-clinical studies and clinical trial results would imply that sclerostin antibodies will emerge as a dominant first- line treatment in the management of osteoporosis.
Assisstant Professor Abdel Ghani Eman
Internal Medicine, Rheumatology and Clinical Immunology Unit, Faculty Of Medicine, University Of Alexandria, 25, Talaat Harb Street, El-Atarrine, Alexandria
|How to cite this article:|
Mona AM, Barakat B, Mona A, Eman AG, Heba B. Sclerostin level in rheumatoid arthritis patients and its relationship to disease severity and bone mineral density.Egypt J Obes Diabetes Endocrinol 2018;4:82-89
|How to cite this URL:|
Mona AM, Barakat B, Mona A, Eman AG, Heba B. Sclerostin level in rheumatoid arthritis patients and its relationship to disease severity and bone mineral density. Egypt J Obes Diabetes Endocrinol [serial online] 2018 [cited 2020 Feb 17 ];4:82-89
Available from: http://www.ejode.eg.net/article.asp?issn=2356-8062;year=2018;volume=4;issue=3;spage=82;epage=89;aulast=Mona;type=0